Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ablynx, a Sanofi company
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Adult male or female ≥ 18 years of age at the time of signing the informed consent form (ICF).
2. Clinical diagnosis of acquired thrombotic thrombocytopenic purpura (aTTP) (initial or recurrent), which included thrombocytopenia and microscopic evidence of red blood cell fragmentation (e.g., schistocytes).
3. Required initiation of daily PE treatment and had received 1 PE treatment prior to randomization
4. Others as defined in the protocol
You may not be if
1. Platelet count ≥100×10E9/L.
2. Serum creatinine level \>200 µmol/L in case platelet count is \> 30×10E9/L
3. Known other causes of thrombocytopenia
4. Congenital TTP (known at the time of study entry).
5. Pregnancy or breast-feeding.
6. Subjects who were previously enrolled in a clinical study with caplacizumab and received caplacizumab or for whom the assigned treatment arm is unknown
7. Others as defined in the protocol
Clareo Health | Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura
